RYU Junnosuke | Nihon University School of Medicine

スポンサーリンク

概要

• 同名の論文著者
• Nihon University School of Medicineの論文著者

関連著者

• Yamanaka Hisashi

  Department Of Rheumatology Tokyo Women's Medical University

• Yoshida Takashi

  Department Of Hematology Japanese Red Cross Nagoya First Hospital

• Yoshino Tadashi

  Department Of Pathology Okayama University Graduate School Of Medicine Dentistry And Pharmaceutical

• Tadashi Yoshino

  Second Department Of Pathology Okayama University Medical School

• Yamanaka Hisashi

  Inst. Of Rheumatology Tokyo Women's Medical Univ. Jpn

• Koike Takao

  Hokkaido University Graduate School Of Medicine

• Harigai Masayoshi

  Tokyo Medical Dental University Graduate School

• Ishiguro Naoki

  Nagoya University Graduate School Of Medicine

• INOKUMA Shigeko

  Japanese Red Cross Medical Center

• RYU Junnosuke

  Nihon University School of Medicine

• Takeuchi Tsutomu

  Division Of Rheumatology School Of Medicine Keio University

• Tanaka Yoshiya

  The First Department Of Internal Medicine School Of Medicine University Of Occupational And Environm

• Yoshino Tadashi

  Department Of Pathology Okayama University Graduate School Of Medicine Dentistry And Pharmaceutical

• Yamanaka Hisashi

  Institute Or Rheumatology Tokyo Women's Medical University

• Yamanaka Hisashi

  Tokyo Women's Medical University

• Freundlich Bruce

  University Of Pennsylvania

• Suzukawa Michio

  Pfizer Japan Inc. Medical Affairs

• Takeuchi Tsutomu

  Keio Univ. School Of Medicine Tokyo Jpn

• Koike Takao

  Hokkaido Univ. Graduate School Of Medicine Hokkaido Jpn

• TANAKA Yoshiya

  University of Occupational and Environmental Health

• YAMANAKA Hisashi

  Tokyo Women's Medical University

• FUJII Koichi

  Pfizer Japan Inc., Medical Affairs

• YOSHINAGA Takunari

  Pfizer Japan Inc., Postmarketing Surveillance

• SUZUKAWA Michio

  Pfizer Japan Inc., Medical Affairs

• HARIGAI Masayoshi

  Tokyo Medical and Dental University

もっと見る 閉じる

著作論文

• Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
• Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
• Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis
• Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study

スポンサーリンク